Skip to main content
SpringerLink
Log in

Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres

  • Interventional
  • Published:
European Radiology Aims and scope Submit manuscript

Abstract

The purpose was to determine the response and survival and to analyse the feasibility of single-session, whole-liver SIRT in patients with non-resectable, otherwise non-responding liver cancer. Thirty-nine patients qualified for SIRT. Eighteen patients suffered from colorectal-cancer metastases (CRC), breast-cancer metastases (MBC, 7), HCC (5) and other tumours (9). Response was assessed by tumour-markers and CT-imaging. At 2–4, 5–7 and 8–9 months follow-up in 3/17, 5/15 and 5/10 of CRC-patients CEA-levels were higher than before. In the MBC group 1–3 and 4–6 months after SIRT tumour-marker-levels were higher in 2/6 and 3/3 patients, respectively. In all HCC-patients AFP-levels dropped 1–3 months after SIRT. Using RECIST, in the CRC-group progressive liver disease (PD) was found in 4/17, 2/12, 2/10 and 2/5 patients at 2–4, 5–8, 9–10 and 12–14 months follow-up. Concerning MBC, after 3 months 7/7 patients presented with stable-disease (SD) or partial-response (PR). At 5–6 months, 1/5 patients showed PD. All HCC-patients showed SD/PR at 2–3 months with no PD at 5–8 months. In the mixed-group 5/6 patients presented with SD/PR at 3–4 months and with SD in 2/3 patients at 5–6 months. The median time-to-PD was 6.5, 8.5 and 8 months for the CRC-, MBC- and mixed-group, respectively. SIRT is a promising, liver-targeted approach for patients with otherwise treatment-refractory liver tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. August DA, Ottow RT, Sugarbaker PH (1984) Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303–324

    Article  PubMed  CAS  Google Scholar 

  2. Deans GT, Parks TG, Rowlands BJ, Spence RA (1992) Prognostic factors in colorectal cancer. Br J Surg 79:608–613

    Article  PubMed  CAS  Google Scholar 

  3. Jardines L, Callans LS, Torosian MH (1993) Recurrent breast cancer: presentation, diagnosis, and treatment. Semin Oncol 20:538–547

    PubMed  CAS  Google Scholar 

  4. Hoe AL, Royle GT, Taylor I (1991) Breast liver metastases-incidence, diagnosis and outcome. J R Soc Med 84:714–716

    PubMed  CAS  Google Scholar 

  5. O’Reilly SM, Richards MA, Rubens RD (1990) Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer 26:574–577

    Article  PubMed  CAS  Google Scholar 

  6. Choti MA (2002) Surgical management of hepatocellular carcinoma: resection and ablation. J Vasc Interv Radiol 13:S197–S203

    Article  PubMed  Google Scholar 

  7. Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38 Suppl 1:S136–S149

    Article  PubMed  Google Scholar 

  8. Llovet JM (2002) Evidence-based medicine in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 17 Suppl 3:S428–S433

    Article  PubMed  Google Scholar 

  9. Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ (2005) Staging and current treatment of hepatocellular carcinoma. Radiographics 25 Suppl 1:S3–S23

    Article  PubMed  Google Scholar 

  10. Kudo M (2005) Early detection and curative treatment of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol 3:S144–S148

    Article  PubMed  CAS  Google Scholar 

  11. Lencioni R, Della Pina C, Bartolozzi C (2005) Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom Imaging 30:401–408

    Article  PubMed  CAS  Google Scholar 

  12. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583

    Article  PubMed  CAS  Google Scholar 

  13. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G (2005) Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 1–9

  14. Rubin D, Nutting C, Jones B (2004) Metastatic breast cancer in a 54-year-old woman: integrative treatment with yttrium-90 radioembolization. Integr Cancer Ther 3:262–267

    Article  PubMed  Google Scholar 

  15. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78–85

    Article  PubMed  CAS  Google Scholar 

  16. Stubbs RS, Cannan RJ, Mitchell AW (2001) Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology 48:333–337

    PubMed  CAS  Google Scholar 

  17. Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ et al (1998) Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40:583–592

    Article  PubMed  CAS  Google Scholar 

  18. Lau WY, Leung WT, Ho S, Leung NW, Chan M, Lin J et al (1994) Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 70:994–999

    PubMed  CAS  Google Scholar 

  19. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z et al (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935

    PubMed  Google Scholar 

  20. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13:S223–S229

    Article  PubMed  Google Scholar 

  21. Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J et al (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41:1673–1681

    PubMed  CAS  Google Scholar 

  22. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK (1997) Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24:293–298

    PubMed  CAS  Google Scholar 

  23. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF et al (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16:205–213

    PubMed  Google Scholar 

  24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumours. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  25. Popperl G, Helmberger T, Munzing W, Schmid R, Jacobs TF, Tatsch K (2005) Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumours. Cancer Biother Radiopharm 20:200–208

    Article  PubMed  Google Scholar 

  26. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:1552–1563

    Article  PubMed  CAS  Google Scholar 

  27. Steele G Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D (1991) A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal tumour Study Group Protocol 6584. J Clin Oncol 9:1105–1112

    PubMed  Google Scholar 

  28. Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F (1991) One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 78:797–801

    Article  PubMed  CAS  Google Scholar 

  29. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP (1991) Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110:13–29

    PubMed  CAS  Google Scholar 

  30. Machover D (1997) A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80:1179–1187

    Article  PubMed  CAS  Google Scholar 

  31. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914

    Article  PubMed  CAS  Google Scholar 

  32. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S et al (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95–98

    PubMed  CAS  Google Scholar 

  33. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J et al (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720

    Article  PubMed  CAS  Google Scholar 

  34. Stubbs RS, Cannan RJ, Mitchell AW (2001) Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 5:294–302

    Article  PubMed  CAS  Google Scholar 

  35. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G (1987) Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5:773–782

    PubMed  CAS  Google Scholar 

  36. Bathe OF, Kaklamanos IG, Moffat FL, Boggs J, Franceschi D, Livingstone AS (1999) Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol 8:35–42

    Article  PubMed  CAS  Google Scholar 

  37. Carlini M, Lonardo MT, Carboni F, Petric M, Vitucci C, Santoro R et al (2002) Liver metastases from breast cancer. Results of surgical resection. Hepatogastroenterology 49:1597–1601

    PubMed  Google Scholar 

  38. Kondo S, Katoh H, Omi M, Hirano S, Ambo Y, Tanaka E et al (2000) Hepatectomy for metastases from breast cancer offers the survival benefit similar to that in hepatic metastases from colorectal cancer. Hepatogastroenterology 47:1501–1503

    PubMed  CAS  Google Scholar 

  39. Maksan SM, Lehnert T, Bastert G, Herfarth C (2000) Curative liver resection for metastatic breast cancer. Eur J Surg Oncol 26:209–212

    Article  PubMed  CAS  Google Scholar 

  40. Raab R, Nussbaum KT, Behrend M, Weimann A (1998) Liver metastases of breast cancer: results of liver resection. Anticancer Res 18:2231–2233

    PubMed  CAS  Google Scholar 

  41. Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 220:145–149

    PubMed  CAS  Google Scholar 

  42. Mack MG, Straub R, Eichler K, Sollner O, Lehnert T, Vogl TJ (2004) Breast cancer metastases in liver: Laser-induced interstitial thermotherapy-local tumour control rate and survival data. Radiology 233(2):400–409

    Article  PubMed  Google Scholar 

  43. Llovet JM, Bruix J (2004) Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. Radiology 230:300–301; author reply 301–302

    Article  PubMed  Google Scholar 

  44. Carr BI (2004) Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10:S107–S110

    Article  PubMed  Google Scholar 

  45. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA et al (2004) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127:S194–S205

    Article  PubMed  CAS  Google Scholar 

  46. Steel J, Baum A, Carr B (2004) Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology 13:73–79

    Article  PubMed  Google Scholar 

  47. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2006) Detection of residual tumour after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 16:80–87

    Article  PubMed  Google Scholar 

  48. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ (2002) Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 29:815–820

    Article  PubMed  CAS  Google Scholar 

  49. Wong CY, Qing F, Savin M, Campbell J, Gates VL, Sherpa KM et al (2005) Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16:1101–1106

    PubMed  Google Scholar 

Download references

Acknowledgement

Parts of these data were collected and evaluated in the context of the dissertation of Mrs. A. Schmitz.

Author information

Authors and Affiliations

  1. Department of Clinical Radiology, University of Munich, Grosshadern Campus, Marchioninistrasse 15, 81377, Munich, Germany

    Tobias F. Jakobs, Ralf-T. Hoffmann, Anna Schmitz, Jürgen Lutz & Maximilian F. Reiser

  2. Department of Nuclear Medicine, University of Munich, Grosshadern Campus, Marchioninistrasse 15, 81377, Munich, Germany

    Gabriele Poepperl, Walter Koch & Klaus Tatsch

  3. Department of Radiology, University of Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany

    Andreas Lubiensky & Thomas Helmberger

Authors
  1. Tobias F. Jakobs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralf-T. Hoffmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gabriele Poepperl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jürgen Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Walter Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Klaus Tatsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andreas Lubiensky
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maximilian F. Reiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Thomas Helmberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias F. Jakobs.

Additional information

Drs. Jakobs and Hoffmann contributed equally to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jakobs, T.F., Hoffmann, RT., Poepperl, G. et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres. Eur Radiol 17, 1320–1330 (2007). https://doi.org/10.1007/s00330-006-0508-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-006-0508-7

Keywords

Search

Navigation